Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Long-term outcomes in juvenile idiopathic arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Mia Glerup
  • Veronika Rypdal
  • Ellen Dalen Arnstad
  • Maria Ekelund
  • Suvi Peltoniemi
  • Kristiina Aalto
  • Marite Rygg
  • Peter Toftedal
  • Susan Nielsen
  • Anders Fasth
  • Lillemor Berntson
  • Ellen Nordal
  • Troels Herlin
  • Nordic Study Group of Pediatric Rheumatology (NoSPeR)
Vis graf over relationer

OBJECTIVE: The present study was undertaken to assess the long-term course, remission rate, and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a population-based setting from the early biologic era.

METHODS: A total of 510 consecutive cases of JIA with disease onset between 1997 and 2000 from defined geographic regions in Denmark, Norway, Sweden, and Finland were prospectively included in this 18-year cohort study. At the follow-up visit, patient-reported demographic and clinical data were collected.

RESULTS: The study included 434 (85%) of the 510 eligible JIA participants. The mean ± SD age was 24.0 ± 4.4 years. The median juvenile arthritis disease activity score in 71 joints (JADAS-71) was 1.5 (interquartile range [IQR] 0-5), with the enthesitis-related arthritis (ERA) category of JIA having the highest median score (4.5 [IQR 1.5-8.5], P = 0.003). In this cohort, 46% of patients still had active disease, and 66 (15%) were treated with synthetic disease-modifying antirheumatic drugs and 84 (19%) with biologics. Inactive disease indicated by a JADAS-71 score of <1 was seen in 48% of participants. Clinical remission off medication (CR) was documented in 33% of the participants with high variability among the JIA categories. CR was most often seen in persistent oligoarticular and systemic arthritis and least often in ERA (P < 0.001).

CONCLUSION: A substantial proportion of the JIA cohort did not achieve CR despite new treatment options during the study period. The ERA category showed the worst outcomes, and in general there is still a high burden of disease in adulthood for JIA.

OriginalsprogEngelsk
TidsskriftArthritis Care & Research
Vol/bind72
Udgave nummer4
Sider (fra-til)507-516
Antal sider10
ISSN2151-464X
DOI
StatusUdgivet - apr. 2020

ID: 58928315